Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Symptoms of anorexia nervosa and bulimia nervosa have differential relationships to borderline personality disorder symptoms.

Miller AE, Racine SE, Klonsky ED.

Eat Disord. 2019 Jul 15:1-14. doi: 10.1080/10640266.2019.1642034. [Epub ahead of print]

PMID:
31305226
2.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

3.

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS.

Mult Scler. 2019 Jun 7:1352458519851981. doi: 10.1177/1352458519851981. [Epub ahead of print]

PMID:
31172849
4.

Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.

Klineova S, Brandstadter R, Fabian MT, Sand IK, Krieger S, Leavitt VM, Lewis C, Riley CS, Lublin F, Miller AE, Sumowski JF.

Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725. [Epub ahead of print]

PMID:
31172846
5.

A pathway for multivariate analysis of ecological communities using copulas.

Anderson MJ, de Valpine P, Punnett A, Miller AE.

Ecol Evol. 2019 Mar 5;9(6):3276-3294. doi: 10.1002/ece3.4948. eCollection 2019 Mar.

6.

The Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MS.

Gross RH, Sillau SH, Miller AE, Farrell C, Krieger SC.

Mult Scler J Exp Transl Clin. 2019 Mar 18;5(1):2055217319837254. doi: 10.1177/2055217319837254. eCollection 2019 Jan-Mar.

7.

Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Tolson JM, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE.

Neurology. 2019 Mar 12;92(11):543. doi: 10.1212/WNL.0000000000007085. No abstract available.

PMID:
30858245
8.

I see your false colours: how artificial stimuli appear to different animal viewers.

Stoddard MC, Miller AE, Eyster HN, Akkaynak D.

Interface Focus. 2019 Feb 6;9(1):20180053. doi: 10.1098/rsfs.2018.0053. Epub 2018 Dec 14.

PMID:
30603072
9.

Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.

Miller AE, Xu X, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS.

J Clin Neurosci. 2019 Jan;59:229-231. doi: 10.1016/j.jocn.2018.09.012. Epub 2018 Oct 20.

10.

Vulnerability and fragility risk indices for non-renewable resources.

Miller AE, Steele N, Tobin BW.

Environ Monit Assess. 2018 Jun 2;190(7):373. doi: 10.1007/s10661-018-6749-5.

PMID:
29860559
11.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

12.

Toward 3D Printed Hydrogen Storage Materials Made with ABS-MOF Composites.

Channell MN, Sefa M, Fedchak JA, Scherschligt J, Bible M, Natarajan B, Klimov NN, Miller AE, Ahmed Z, Hartings MR.

Polym Adv Technol. 2018 Feb;29(2):867-873. doi: 10.1002/pat.4197. Epub 2017 Oct 19.

13.

Central vein sign in multiple sclerosis: Ready for front and center?

Miller AE, Calabresi PA.

Neurology. 2018 Apr 3;90(14):631-632. doi: 10.1212/WNL.0000000000005241. Epub 2018 Mar 7. No abstract available.

PMID:
29514945
14.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
15.

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.

Miller AE.

Ther Adv Neurol Disord. 2017 Dec;10(12):381-396. doi: 10.1177/1756285617722500. Epub 2017 Sep 13. Review.

16.

Neurodevelopmental outcomes for high-risk neonates in a low-resource setting.

Milner KM, Duke T, Steer AC, Kado JH, Koyamaibole L, Kaarira R, Namudu K, Woolfenden S, Miller AE, O'Heir KE, Neal EFG, Roberts G.

Arch Dis Child. 2017 Nov;102(11):1063-1069. doi: 10.1136/archdischild-2017-312770. Epub 2017 Aug 28.

PMID:
28847882
17.

Warming drives a front of white spruce establishment near western treeline, Alaska.

Miller AE, Wilson TL, Sherriff RL, Walton J.

Glob Chang Biol. 2017 Dec;23(12):5509-5522. doi: 10.1111/gcb.13814. Epub 2017 Aug 17.

PMID:
28712139
18.

Conformational behavior and stacking interactions of contorted polycyclic aromatics.

Guan Y, Jones ML, Miller AE, Wheeler SE.

Phys Chem Chem Phys. 2017 Jul 19;19(28):18186-18193. doi: 10.1039/c7cp02637d.

PMID:
28513691
19.

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups.

Mult Scler. 2018 Apr;24(4):535-539. doi: 10.1177/1352458517695468. Epub 2017 Mar 17.

20.

Teriflunomide in multiple sclerosis: an update.

Miller AE.

Neurodegener Dis Manag. 2017 Feb;7(1):9-29. doi: 10.2217/nmt-2016-0029. Epub 2016 Dec 12.

21.

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.

Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010. Epub 2016 Nov 3.

22.

Tree-ring isotopes reveal drought sensitivity in trees killed by spruce beetle outbreaks in south-central Alaska.

Csank AZ, Miller AE, Sherriff RL, Berg EE, Welker JM.

Ecol Appl. 2016 Oct;26(7):2001-2020. doi: 10.1002/eap.1365. Epub 2016 Sep 21.

PMID:
27755740
23.

Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices.

Tornatore C, Phillips JT, Khan O, Miller AE, Hughes M.

Neurol Clin Pract. 2016 Aug;6(4):329-338. Review.

24.

Multiple sclerosis: Rapid diagnosis or right diagnosis?

Miller AE, Pelletier D.

Neurology. 2016 Aug 16;87(7):652-3. doi: 10.1212/WNL.0000000000002994. Epub 2016 Jul 15. No abstract available.

PMID:
27421542
25.

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B.

BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2.

26.

The chemical, mechanical, and physical properties of 3D printed materials composed of TiO2-ABS nanocomposites.

Skorski M, Esenther J, Ahmed Z, Miller AE, Hartings MR.

Sci Technol Adv Mater. 2016;17(1):89-97. Epub 2016 Apr 1.

27.

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.

Miller AE.

Mult Scler. 2016 Oct;22(11):1402-1404. Epub 2016 Jun 8. No abstract available.

PMID:
27279589
28.

Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis.

Miller AE.

Continuum (Minneap Minn). 2016 Jun;22(3):851-63. doi: 10.1212/CON.0000000000000327. Review.

PMID:
27261686
29.

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.

Mäurer M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, Miller AE, Dive-Pouletty C, Bozzi S, O'Connor PW.

Mult Scler Relat Disord. 2016 May;7:33-40. doi: 10.1016/j.msard.2016.02.012. Epub 2016 Feb 17.

30.

Multiple sclerosis disease-modifying therapy and pregnancy.

Miller AE.

Mult Scler. 2016 May;22(6):715-6. doi: 10.1177/1352458516642316. No abstract available.

PMID:
27207870
31.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
32.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

33.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

34.

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW.

Mult Scler J Exp Transl Clin. 2015 Dec 7;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015 Jan-Dec.

35.

Rheumatic Heart Disease-Attributable Mortality at Ages 5-69 Years in Fiji: A Five-Year, National, Population-Based Record-Linkage Cohort Study.

Parks T, Kado J, Miller AE, Ward B, Heenan R, Colquhoun SM, Bärnighausen TW, Mirabel M, Bloom DE, Bailey RL, Tukana IN, Steer AC.

PLoS Negl Trop Dis. 2015 Sep 15;9(9):e0004033. doi: 10.1371/journal.pntd.0004033. eCollection 2015.

36.

Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.

Miller AE.

Clin Ther. 2015 Oct 1;37(10):2366-80. doi: 10.1016/j.clinthera.2015.08.003. Epub 2015 Sep 11. Review.

37.

Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.

Miller AE.

Expert Rev Clin Immunol. 2015 Feb;11(2):181-94. doi: 10.1586/1744666X.2015.993611. Epub 2014 Dec 16. Review.

PMID:
25511008
38.

Assessing the Comparative Outcomes from Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of "Number Needed to Treat" Analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Leist TP.

Value Health. 2014 Nov;17(7):A392. doi: 10.1016/j.jval.2014.08.864. Epub 2014 Oct 26. No abstract available.

39.

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group.

Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.

PMID:
25192851
40.

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW.

J Neurol. 2014 Sep;261(9):1781-8. doi: 10.1007/s00415-014-7395-7. Epub 2014 Jun 28.

41.

Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P.

Brain. 2014 Aug;137(Pt 8):2271-86. doi: 10.1093/brain/awu139. Epub 2014 Jun 3. Erratum in: Brain. 2015 Jul;138(Pt 7):e367.

42.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

43.

Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.

Katz Sand I, Krieger S, Farrell C, Miller AE.

Mult Scler. 2014 Oct;20(12):1654-7. doi: 10.1177/1352458514521517. Epub 2014 Feb 3.

PMID:
24493475
44.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
45.

Clinical course in multiple sclerosis patients presenting with a history of progressive disease.

Pandey KS, Krieger SC, Farrell C, Hannigan C, DeAngelis T, Miller AE, Lublin FD.

Mult Scler Relat Disord. 2014 Jan;3(1):67-71. doi: 10.1016/j.msard.2013.05.004. Epub 2013 Jul 19.

PMID:
25877975
46.

Concurrent zero-dimensional and one-dimensional biomineralization of gold from a solution of Au3+ and bovine serum albumin.

Hartings MR, Benjamin N, Briere F, Briscione M, Choudary O, Fisher TL, Flynn L, Ghias E, Harper M, Khamis N, Koenigsknecht C, Lazor K, Moss S, Robbins E, Schultz S, Yaman S, Haverhals LM, Trulove PC, De Long HC, Miller AE, Fox DM.

Sci Technol Adv Mater. 2013 Nov 20;14(6):065004. eCollection 2013 Dec.

47.

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group.

Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14.

PMID:
24126064
48.

Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME.

Miller AE, Cohen BA, Krieger SC, Markowitz CE, Mattson DH, Tselentis HN.

Mult Scler. 2014 Jan;20(1):18-23. doi: 10.1177/1352458513495937. Epub 2013 Aug 6.

PMID:
23921134
49.

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L.

J Neurol. 2013 Oct;260(10):2472-80. doi: 10.1007/s00415-013-6979-y. Epub 2013 Jul 14.

50.

Causes of puerperal and neonatal sepsis in resource-constrained settings and advocacy for an integrated community-based postnatal approach.

Miller AE, Morgan C, Vyankandondera J.

Int J Gynaecol Obstet. 2013 Oct;123(1):10-5. doi: 10.1016/j.ijgo.2013.06.006. Epub 2013 Jul 5. Review.

PMID:
23830869

Supplemental Content

Loading ...
Support Center